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(HR 1.6; 95 CI 1.0–2.5; 2 studies; OR 1.3; 95% CI 0.9–1.9; 3 stud-
ies), or PFO and migraine (OR 1.0; 95% CI 0.6–1.6; 1 study). It 
was not possible to look for interactions or effect modifiers. 
These results are limited by sources of bias within individual 
studies.  Conclusions: The overall pairwise associations be-
tween PFO, cryptogenic ischemic stroke and migraine do 
not strongly suggest a causal role for PFO. Ongoing random-
ized trials of PFO closure may need larger numbers of par-
ticipants to detect an overall beneficial effect. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Modifiable risk factors for ischemic stroke may be tar-
gets for primary or secondary prevention, especially if the 
strength of their association suggests that they might be 
causal. Up to one third of ischemic strokes are ‘crypto-
genic’ because a recognized cause is not identified  [1] . 
One putative cause of cryptogenic ischemic stroke is par-
adoxical embolism through patent foramen ovale (PFO) 
 [2] , itself a consequence of failure of the septa on either 
side of the fetal interatrial shunt to fuse after birth. More-
over, suggested associations between PFO and migraine 
are of interest because migraine has also been considered 
a risk factor for ischemic stroke  [3] .
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 Abstract 
 Background: Observational data have reported associa-
tions between patent foramen ovale (PFO), cryptogenic 
stroke and migraine. However, randomized trials of PFO clo-
sure do not demonstrate a clear benefit either because the 
underlying association is weaker than previously suggested 
or because the trials were underpowered. In order to resolve 
the apparent discrepancy between observational data and 
randomized trials, we investigated associations between (1) 
migraine and ischemic stroke, (2) PFO and ischemic stroke, 
and (3) PFO and migraine.  Methods: Eligibility criteria were 
consistent; including all studies with specifically defined ex-
posures and outcomes unrestricted by language. We fo-
cused on studies at lowest risk of bias by stratifying analyses 
based on methodological design and quantified associa-
tions using fixed-effects meta-analysis models.  Results: We 
included 37 studies of 7,686 identified. Compared to reports 
in the literature as a whole, studies with population-based 
comparators showed weaker associations between migraine 
with aura and cryptogenic ischemic stroke in younger wom-
en (OR 1.4; 95% CI 0.9–2.0; 1 study), PFO and ischemic stroke 
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 Non-blinded and non-randomized interventional 
studies of percutaneous PFO closure have suggested ben-
efits of PFO closure on recurrent cryptogenic ischemic 
stroke  [4–6] and refractory migraine  [7–10] , but random-
ized controlled trials have not confirmed these effects  [11, 
12] . This suggests the possibility that the reported obser-
vational data, like the uncontrolled trials, may have been 
biased or confounded. While the randomized trials may 
have been underpowered to detect a benefit of closure, 
this may have been driven by the original estimated effect 
size being based on a stronger association than is actu-
ally the case.
 In this context, it is timely to review the observational 
studies and the way in which previous meta-analyses ad-
dressed methodological biases when pooling estimates of 
association. To date, systematic reviews have suggested 
significant associations between migraine and ischemic 
stroke [odds ratio (OR) 2.2; 95% confidence intervals (CI) 
1.6–3.0]  [13] , PFO and ischemic stroke (OR 2.9; 95% CI 
2.1–4.0)  [14] , and PFO and migraine (OR 2.5; 95% CI 2.0–
3.1)  [15] . However, the degree of bias in observational data 
differs between studies, and not accounting for these dif-
ferences may lead to propagation of these biases in the 
pooled estimates  [16] . One approach to this issue is to 
stratify analyses based on methodological design, there-
by reducing heterogeneity in observational studies in the 
meta-analysis.
 Here, we set out to refine the interpretation of the cur-
rent literature in order to (1) quantify the interrelated as-
sociations between migraine, PFO and stroke, and (2) to 
inform the design of randomized trials of PFO closure. 
Therefore, we undertook a series of systematic reviews 
and meta-analyses investigating the pairwise associa-
tions between a past history of migraine, PFO and the 
occurrence of cryptogenic ischemic stroke or all ische-
mic stroke ( fig. 1 ), applying consistent eligibility criteria 
across all three relationships. We specifically gave prior-
ity to population-based studies, prospective cohort de-
signs and studies that had matched or adjusted for known 
confounders for stroke, with a view to stratifying by study 
design and restricting meta-analyses to methodological-
ly similar population sampling frames.
 Methods 
 The protocol followed the Meta-analysis of Observational 
Studies in Epidemiology (MOOSE) guidelines  [17] (online
suppl. checklist; for all online supplementary material, see www.
karger.com/doi/10.1159/000341924; study characteristics of all in-
cluded studies are given in full, along with referenced PRISMA 
flowchart detailing excluded studies).
 Eligibility Criteria 
 We searched for cohort, case-control or cross-sectional studies 
unrestricted by demographic features or language of publication, 
PFO
Population-based
Community-convenience
Hospital-convenience
Migraine
Based on IHS criteria
Diagnosed by either:
• TTE
• TEE
• TCD
Clinical definition based on
WHO criteria, supported by
radiological findings, and
additionally for cryptogenic
stroke:
• Carotid stenosis <50%
• No arrythmias
• No major structural heart
  disease (not including PFO)
• Non-lacunar syndrome
Cryptogenic stroke
Ischemic stroke
 Fig. 1. Diagramatic representation of sys-
tematically examined associations. Sum-
mary of relationships between pairwise as-
sociations, outlining operationalized defi-
nitions of exposures and outcomes. 
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which had been conducted in population or hospital settings, and 
which compared the associations between any two relationships 
( fig. 1 ). We required studies defining ischemic stroke by WHO cri-
teria (supported by radiological findings) and cryptogenic isch-
emic strokes defined as non-lacunar clinical syndromes without 
carotid stenosis  1 50%, cardiac arrhythmias or structural heart 
disease (excluding PFO). To be included, we required studies that 
did not report an outcome of cryptogenic ischemic stroke but in-
stead report total first-ever or recurrent ischemic stroke with ad-
justment for known risk factors for ischemic stroke (specifically 
hypertension, diabetes, hypercholesterolemia, atrial fibrillation, 
smoking, alcohol, family history). We included studies defining 
migraine according to the International Headache Society (IHS) 
classification  [18, 19] . PFO must have been diagnosed by contrast 
transthoracic echocardiogram (TTE), transesophageal echocar-
diogram (TEE) or transcranial Doppler (TCD) ultrasound during 
Valsalva maneuver. Cerebral infarction in the context of complex 
migraine is a well-recognized clinical phenomenon, and so studies 
reporting migrainous infarction were not considered further. We 
did not include data from placebo arms of randomized trials be-
cause interventional studies are not required to use a consistent 
sampling frame. We excluded studies of children, pregnant wom-
en and those reporting associations within family pedigrees.
 Information Sources 
 D.D. searched Medline from 1950 on PubMed, Embase from 
1980 on NHS Evidence Health Information Resources, and Sci-
ence Citation Index on Web of Science from 1950, all to April 
2012. We sought journal publications as well as conference ab-
stracts and contacted authors of abstracts to determine whether 
further data had been published. In addition, the bibliographies 
of included articles and other systematic reviews were screened.
 Search Terms and Study Selection 
 D.D. used comprehensive textword and Medical Subject Head-
ing (MeSH) to find relevant studies in humans (full search terms 
given in MOOSE checklist, online suppl. material). Four review-
ers (D.D., J.G., P.W., B.S.) independently screened articles by title 
and abstract after de-duplication through first author surname, 
title and first page number with those for full-text review, and 
subsequent inclusion agreed by consensus. We sought every pub-
lication relating to each included study using a search strategy 
based on the full name of the study or its acronym, as well as for-
ward searching using citation index databases.
 Data Extraction 
 Two reviewers independently extracted study data using stan-
dardized forms developed after piloting and critically appraised 
each study using the Newcastle-Ottawa scale (NOS)  [20] . The 
NOS assesses population selection, comparability of cases and 
controls, and adequacy of outcome assessment (including out-
come ascertainment and attrition). In keeping with the MOOSE 
guidelines, we did not use the NOS to determine study inclusion 
but to guide the classification of studies by similarities in design.
 We classified a hierarchy of population sampling methods 
from lowest to highest risk of bias (online suppl. table S1), where 
‘population-based’ refers to a sampling frame including all sub-
groups within a geographical population, unrestricted by demo-
graphic or clinical features, ‘community-convenience’ indicates 
selection from outpatient participants, and ‘hospital-conve-
nience’ denotes participants recruited only from hospital inpa-
tients. We considered cryptogenic ischemic stroke and ischemic 
stroke as separate outcomes.
 Data Analysis 
 J.G. and P.W. conducted the statistical analyses using STATA 
version 10.1. Where multiple estimates of association were report-
ed, the most adjusted estimate was used in analyses. Summary 
statistics for hazard ratios (HR), relative risks (RR) or OR and 
their accompanying 95% CI were calculated using a Mantel-
Haenszel fixed-effect model. Statistical heterogeneity was as-
sessed with the I 2 statistic.
 Results 
 We identified 7,686 studies (online suppl. MOOSE 
checklist). We reviewed the full text of 116 studies, and 
excluded studies are fully referenced in the PRISMA flow 
diagrams (online suppl. fig. S1–S3). Supplementary table 
S2 gives further details of any study considered in any pre-
vious systematic reviews and meta-analyses, if any such 
study was excluded here. Finally, we included 37 studies 
in this review. We have separately summarized study 
characteristics, their results (and their meta-analysis, 
where appropriate) and risk of bias according to the asso-
ciation being investigated. Full details of all reviewed 
studies are given in online supplementary tables S3–S5. 
 Table 1 shows the characteristics of only those included 
studies with either population-based sampling frames or 
a prospective design.
 Migraine and Ischemic Stroke 
 We identified one prospective and one population-
based case-control study of women with migraine with 
aura with conflicting results ( fig. 2 ).
 Prospective Studies. The Women’s Health Study 
(WHS), which included 27,840 female health care profes-
sionals aged  1 45 years, was the only prospective study in 
this section to meet all inclusion criteria  [21] . The most 
fully adjusted model estimated an association with isch-
emic stroke (HR 1.2; 95% CI 0.9–1.7 for migraine and HR 
1.9; 95% CI 1.2–3.1 for active migraine with aura).
 Population-Based Case-Control Studies. One case-
control study used a population-based sampling frame 
 [22] . In women aged 15–49 years, 192 participants with 
migraine with aura were not associated with cryptogenic 
stroke (adjusted OR 1.4; 95% CI 0.9–2.0). In a small sub-
group of these women with known PFO, there was no 
evidence of a different association (adjusted OR 2.1; 95% 
CI 0.8–5.3; n = 21) compared to the group known to not 
have PFO (adjusted OR 1.5; 95% CI 1.0–2.2; n = 142).
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Table 1. C haracteristics of included population-based and prospective studies
First
author 
year
Design Follow-
up
years
Age
(SD)
years
Population Exposure Outcome Confounders Method of 
addressing 
confounding
Migraine-stroke
Kurth,
2006 [21]
Cohort 10 55 
(7.5)
Female health
professionals
IHS
structured 
interview
Ischemic stroke
adjusted for
known RF
Age, HTN, DM, chol, 
smoking, BMI, EtOH, 
menopause, HRT, HTN meds, 
chol meds, OCP, FHx MI
Cox regression
MacClellan,
2007 [22]
Case-
control
NA 39
(5)
Cases: women identified 
through record linkage;
controls: 10 year age-
region-race matched 
population
IHS-based
(MA only)
Cryptogenic age, ethnicity, region, HTN, 
IHD, smoking, OCP
Logistic
regression
PFO-stroke
Di Tullio,
2007 [31]
Cohort 6.6* 69
(10)
Stroke free, population-
based
TTE Ischemic stroke
adjusted for known RF
Age, sex, ethnicity, HTN,
DM, smoking, chol, AF,
aspirin use
Cox regression
Meissner,
2006 [30]
Cohort 5.1 67 
(13)
Stroke/cardiac disease-
free, population-based
TEE Death, first or recurrent 
stroke/TIA
Age, sex, HTN, DM, IHD, 
smoking, chol, AF, ASA
Cox regression
Mas,
2001 [51]
Cohort 3.2 42 
(6.5)
Cryptogenic stroke,
hospital
TEE and
TTE
Death or any recurrent 
cardio- or
cerebrovascular event
Age, sex, HTN, DM, chol, 
smoking
Cox regression
De Castro,
2000 [61]
Cohort 2.6 50 
(14)
Cryptogenic stroke/TIA, 
tertiary
TEE Death or any recurrent 
stroke/TIA
Age, ‘classical vascular RF’, 
treatment
Cox regression
Serena,
2008 [62]
Cohort 2.0 47 
(15)
Cryptogenic
stroke/TIA, tertiary 
TCD then
TEE
Any recurrent
cerebrovascular event
Age, sex, HTN, DM, IHD, 
smoking, EtOH, migraine,
ASA
Logistic
regression
Feurer,
2010 [52]
Cohort 4.0 59 
(15)
Ischemic stroke,
hospital 
TCD Death or any recurrent 
cardio- or
cerebrovascular event
Age, sex, HTN, DM, IHD, 
smoker, obesity, AF
Cox regression
Comess,
1994 [63]
Cohort 1.5 61 
(10)
Ischemic stroke/TIA, 
hospital
TEE Any recurrent stroke
or TIA
Age, sex, HTN, DM, IHD, 
aspirin/warfarin use,
carotid disease
Frequency 
matched
Petty,
2006 [33]
Case-
control
NA 70 
(10)
Cases: cryptogenic
stroke, population;
controls: random
population
TEE Cryptogenic stroke 
adjusted for known RF
Age, sex, HTN, IHD, LVF, 
smoking, AF, No. of
contrast injections, ASA
Logistic 
regression
Sastry,
2006 [32]
Case-
control
NA 33
(3)
Cases: ischemic stroke, 
hospital (2);
controls: age-sex-GP-
matched population
TCD
validated
with TEE in
subgroup
Ischemic stroke
adjusted for known RF
HTN, DM, smoking,
chol
Conditional 
logistic
regression
Roijer,
1997 [34]
Case-
control
NA 69 
(12)
Cases: stroke, hospital;
controls: age-sex matched, 
population
TEE Cryptogenic stroke Age, sex, HTN, DM,
IHD, AF
None
PFO-migraine
Rundek,
2008 [45]
Cross-
sectional
NA 69 
(10)
Cases: stroke-free cohort, 
population-based;
controls: cross-sectional 
TTE Age, sex, ethnicity, HTN,
DM, chol, smoking
Logistic
regression
H TN = Hypertension; DM = diabetes mellitus; IHD = ischemic heart 
disease; LVF = left ventricular failure; chol = hypercholesterolemia; OCP = 
oral contraceptive pill; ASA = atrial septal aneurysm; TIA = transient is-
chemic attack; meds = medications; EtOH = alcohol intake; FHx MI = fa-
mily history of myocardial infarction; HRT = hormone replacement thera-
py; AF = atrial fibrillation; RF = risk factor; MA = migraine with aura. * 
Only mean follow-up reported.
Only prospective studies and/or population-based studies are present-
ed here. Full characteristics of all considered studies are given in suppl. 
tables 3–5.
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Study Stroke
(migraine:
no migraine)
Control
(migraine:
no migraine)
Effect estimate
(95% CI)
PROSPECTIVE DESIGN
Community-convenience sample
Ischemic stroke (time-to-event analysis, HR)
Kurth, 2006 [21] 47:204 5,125:22,715 1.20 (0.90, 1.70)
CROSS-SECTIONAL DESIGN
Community-convenience sample
Cryptogenic stroke (OR)
Schwaag, 2003 [23] xx:42 20:140 1.10 (0.50, 2.40)
Ischemic stroke (OR)
Carolei, 1996 [24] 46:262 54:537 1.70 (1.10, 2.80)
Hospital-convenience sample
Ischemic stroke (OR)
Chang, 1999 [27] 26:385 26:xx 3.50 (1.30, 9.60)
Barinagarrementeria, 1998 [28] 20:90 13:109 1.60 (0.80, 3.50)
Tzourio, 1995 [25] 43:29 52:121 3.50 (1.80, 6.40)
Tzourio, 1993 [26] 41:171 34:178 1.30 (0.80, 2.30)
Subtotal (I2 = 57.8%, p = 0.069) 2.00 (1.43, 2.79)
0.25 0.5 1 2 4 8 16
Study Stroke
(migraine:
no migraine)
Control
(migraine:
no migraine)
Effect estimate
(95% CI)
PROSPECTIVE DESIGN
Community-convenience sample
Ischemic stroke (time-to-event analysis, HR)
Kurth, 2006 [21] 18:1,434 204:22,715 1.90 (1.20, 3.10)
CROSS-SECTIONAL DESIGN
Population-based sample
Cryptogenic stroke (OR)
MacClellan, 2007 [22] 75:117 178:436 1.40 (0.90, 2.00)
Community-convenience sample
Ischemic stroke (OR)
Carolei, 1996 [24] 8:300    xx:xx 5.20 (1.40, 20.00)
Hospital-convenience sample
Ischemic stroke (OR)
Tzourio, 1995 [25] 10:62 10:163 6.20 (2.10, 18.00)
Chang, 1999 [27] 7:404 9:xx 3.80 (1.30, 11.00)
Henrich, 1989 [29] 11:78 9:169 2.60 (0.90, 7.20)
Tzourio, 1993 [26] 9:203 7:205 1.30 (0.50, 3.80)
Subtotal (I2 = 35.0%, p = 0.202) 2.91 (1.72, 4.92)
0.25 0.5 1 2 4 8 16
 Fig. 2.  a Meta-analysis of the reported associations between mi-
graine and ischemic stroke (by study design and sampling frame). 
 b Meta-analysis of the reported associations between migraine 
with aura and ischemic stroke (by study design and sampling 
frame). Forest plot showing results of meta-analysis. Studies are 
grouped by design and sampling frame. Black squares are propor-
tional to the study size, lines represent 95% confidence intervals. 
The open diamond summarizes the pooled estimate within each 
stratum. Absolute values are given for cases and controls (numera-
tor and denominator), xx indicates where these were not reported. 
 a 
 b 
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 Non-Population-Based Case-Control Studies. Figure 4a 
shows the estimated associations for any history of mi-
graine and ischemic stroke, stratified by study design. 
The reported association of one study comparing crypto-
genic stroke cases with community-convenience controls 
(OR 1.1; 95% CI 0.5–2.4)  [23] was somewhat weaker than 
the association in a study comparing ischemic stroke cas-
es  [24] with community-convenience controls (OR 1.7; 
95% CI 1.1–2.8) than the pooled risk estimate of studies 
of ischemic stroke with hospital-convenience controls 
 [25–28] (pooled OR 2.0; 95% CI 1.4–2.8; I 2 = 58%).  Figure 
2 b shows the meta-analysis of studies reporting migraine 
with aura subtypes  [25–27, 29] . This yielded a pooled OR 
of 2.9 and 95% CI of 1.7–4.9 (I 2 = 35%). Failure to account 
for atrial fibrillation was a feature common to all these 
studies.
 PFO and Ischemic Stroke 
 Pooled results from prospective and population-based 
studies did not demonstrate an association between PFO 
and ischemic stroke ( fig. 3 ). 
 Population-Based Prospective Studies.  We identified 2 
population-based cohort studies in essentially stroke-
free populations where ischemic stroke adjusted for 
known vascular risk factors was the main outcome 
( fig. 3 )  [30, 31] . The pooled HR for risk of primary isch-
emic stroke in relation to PFO was 1.6 with 95% CI of 
1.0–2.5 (I 2 = 0%). The other prospective studies reported 
no statistically significant association (where p  ! 0.05), 
either individually or if pooled (OR 1.0; 95% CI 0.6–1.8; 
 I 2 = 0%) ( fig. 3 ).
 Population-Based Case-Control Studies. Three studies 
compared cryptogenic ischemic stroke with healthy con-
trols sampled from the general population, yielding a 
pooled OR of 1.3 and 95% CI of 0.9–1.8 (I 2 = 0%) ( fig. 3 ) 
 [32–34] . Two studies performed subgroup analyses to as-
sess the association of larger shunts with stroke  [32, 33] . 
Pooling the association across studies yielded an OR of 
1.3 and 95% CI of 0.8–2.1 (I 2 = 79%).
 Non-Population-Based Case-Control and Cross-Sec-
tional Studies. A total of 10 studies compared cryptogen-
ic ischemic stroke with: (1) healthy community-conve-
nience controls  [35, 36] ; (2) controls undergoing echocar-
diography for non-stroke indications  [37–39] , or (3) 
ischemic stroke of known cause, adjusted for other vas-
cular risk factors  [40–44] . When subdivided by a popula-
tion sampling frame, the pooled ORs for community-
convenience and hospital-convenience controls were 1.9 
(95% CI 1.2–3.1; I 2 = 39%) and 2.8 (95% CI 2.1–3.6;  I 2 = 
27%), respectively ( fig. 3 ).
 PFO and Migraine 
 We found one population-based study, and this did not 
show an association between PFO and migraine ( fig. 4 ).
 Cross-Sectional and Case-Control Studies. In addition 
to the stroke outcomes above, the population-based NO-
MAS study  [45] reported the association between PFO 
and migraine as OR of 1.0 (95% CI 0.6–1.6), and this was 
not different when only considering migraine with aura 
(OR 1.0; 95% CI 0.7–1.7). Garg et al.  [46] reported no as-
sociation with PFO (OR 1.0; 95% CI 0.6–1.7) in 144 stroke-
free migraineurs recruited from a tertiary clinic who 
were compared to age- and sex-matched controls selected 
from a register of healthy volunteers. The other case-con-
trol study used convenience controls, and the estimate for 
any history of migraine and PFO was OR of 3.9 (95% CI 
1.4–11) ( fig. 4 )  [47] . Two further abstracts were identified 
that reported population-based associations, and full 
publication of both studies is awaited  [48, 49] .
 Discussion 
 Summary of Evidence 
 For each pairwise association between migraine, PFO 
and ischemic stroke, there is inconsistent evidence, and 
the strength of the reported associations is dependent on 
study design. Overall, associations apparent in case-con-
trol studies were not evident in the more generalizable 
population-based studies with sufficiently valid assess-
ments of exposure and outcome.
 Migraine and Ischemic Stroke.  In the subset of younger 
women with migraine with aura and cryptogenic stroke, 
there is no clear association  [22] , and there are no studies 
with a strict population-based sampling frame describing 
this relationship in men (of any age). However, there is 
some evidence from a prospective study suggesting an as-
sociation in female health workers aged  1 45 years with 
migraine with aura and ischemic stroke  [21] , though atrial 
fibrillation was not accounted for despite a separate report 
demonstrating an association between this and stroke  [50] .
 PFO and Ischemic Stroke.  Cohort studies did not dem-
onstrate an association between PFO and first-ever  [30, 
31] or recurrent ischemic stroke risk  [51, 52] , findings 
which are supported by three case-control studies com-
paring PFO in cryptogenic ischemic stroke with popula-
tion-based controls  [32–34] .
 PFO and Migraine.  The only population-based study 
investigating the association between PFO and migraine 
with or without aura was cross-sectional and found no 
association  [45] .
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Study Stroke
(PFO:no PFO)
Control
(PFO:no PFO)
Effect estimate
(95% CI)
PROSPECTIVE DESIGN
Population-based sample
Primary stroke (time-to-event analysis)
Meissner, 2006 [30] 12:140 29:437 1.46 (0.74, 2.88)
Di Tullio, 2007 [31] 12:164 56:936 1.64 (0.87, 3.09)
Subtotal (I2 = 0.0%, p = 0.806) 1.55 (0.98, 2.47)
Hospital-convenience sample
Recurrent stroke (time-to-event analysis)
Mas, 2001 [51] 13:216 16:304 1.34 (0.62, 2.90)
Feurer, 2010 [52] 10:254 32:509 0.81 (0.39, 1.69)
Subtotal (I2 = 0.0%, p = 0.354) 1.03 (0.60, 1.75)
Recurrent stroke (rate ratio)
Comess, 1994 [63]   xx:xx    xx:xx 2.00 (0.84, 4.74)
Recurrent stroke (OR)
Serena, 2008 [62] 16:297 12:198 0.94 (0.36, 2.40)
RETROSPECTIVE DESIGN
Hospital-convenience sample
Recurrent stroke (rate ratio)
Cujec, 1999 [64] 14:52 6:38 5.30 (1.60, 17.60)
CROSS-SECTIONAL DESIGN
Population-based sample
Cryptogenic stroke (OR)
Roijer, 1997 [34] 17:50 15:43 0.97 (0.04, 2.18)
Sastry, 2006 [32] 43:58 38:63 1.34 (0.74, 2.42)
Petty, 2006 [33] 33:100 128:391 1.30 (0.80, 2.10)
Subtotal (I2 = 0.0%, p = 0.954) 1.30 (0.90, 1.88)
Community-convenience sample
Cryptogenic stroke (OR)
Jones, 1994 [36] 14:57 31:171 1.35 (0.67, 2.72)
Serena, 1998 [37] 30:25 32:68 2.55 (1.30, 5.02)
Subtotal (I2  = 39.0%, p = 0.200) 1.88 (1.15, 3.05)
Hospital-convenience sample
Cryptogenic stroke (OR)
Force, 2008 [42] 17:45 4:66 3.80 (0.71, 21.00)
Di Tullio, 1992 [41] 19:26 7:94 7.20 (2.40, 22.00)
Cabanes, 1993 [38] 36:28 9:41 3.90 (1.50, 10.00)
Negrao, 2007 [44] 35:53 18:62 3.30 (1.50, 7.40)
Cerrato, 2002 [40] 43:63 12:57 2.20 (1.20, 4.90)
Schuchlenz, 2000 [39] 24:22 13:33 1.50 (0.80, 2.70)
Handke, 2007 [43] 77:150 34:242 3.10 (2.00, 5.10)
Subtotal (I2 = 27.0%, p = 0.223) 2.76 (2.09, 3.63)
Retinal/cerebral ischemia (OR)
Chen, 1991 [65] 7:27 15:19 3.10 (1.00, 8.90)
0.25 0.5 1 2 4 8 16
 Fig. 3. Meta-analysis of the reported associations between PFO 
and ischemic stroke (by study design and sampling frame). Forest 
plot showing results of meta-analysis. Studies are grouped by de-
sign and sampling frame. Black squares are proportional to the 
study size, lines represent 95% confidence intervals. The open di-
amond summarizes the pooled estimate within each stratum. Ab-
solute values are given for cases and controls (numerator and de-
nominator), xx indicates where these were not reported. 
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 Strengths and Limitations 
 This is the first review on this topic to stratify analyses 
on methodological grounds, which may explain why our 
conclusions differ from earlier meta-analyses. In apply-
ing a consistent approach to article selection and critical 
appraisal, we have been able to assess the evidence sys-
tematically across the three relationships. Our approach 
to meta-analysis has had the advantage of yielding low 
statistical measures of heterogeneity (I 2 ). While there are 
other procedures for addressing heterogeneity  [53] , our 
method has sound face validity. By identifying the obser-
vational studies at least risk of bias, we base our conclu-
sions on the most epidemiologically applicable data.
 For studies of migraine and ischemic stroke, there was 
inconsistency in controlling for possible confounders, in 
particular atrial fibrillation. Accordingly, the one pro-
spective study to report a positive association (the WHS) 
should be considered with caution in this light.
 The two population-based prospective studies of PFO 
and first-ever stroke risk had very similar results and did 
not demonstrate an association. It is possible that longer 
follow-up might have detected a small contribution of 
PFO to ischemic stroke risk. However, given the age-relat-
ed incidence of more well-recognized risk factors for isch-
emic stroke, the power to detect an attributable risk from 
PFO probably diminishes with time. The population-
based case-control studies were in agreement, though
the findings from Roijer et al.  [34] are problematic because 
the age matching was unsuccessful, with controls being 
younger. In addition, although ‘major potential cardio-
embolic sources’ were excluded, a higher frequency of 
atrial fibrillation was reported in the cases. Despite these 
possible biases, the overall conclusions are acceptable in 
the context of the other population-based studies.
 The only population-based data on the association be-
tween migraine and PFO assessed migraine in those re-
porting a past history of headache during a screening in-
terview. Given the mean age of the participants (69 years), 
it has been suggested that recall bias may have caused an 
underestimation of migraine history, though the reported 
prevalence of migraine is consistent with other estimates 
from the general population  [45] . Finally, because the 
pooled results from population-based studies did not 
demonstrate any clear associations, it was not possible to 
examine for any potential interactions or effect modifiers.
 There are three main reasons that population-based 
observational studies may consistently report no associa-
tion between migraine, PFO and cryptogenic stroke. 
Firstly, any misclassification of exposure status may bias 
any true association towards the null. In particular, stud-
ies employing TTE may have not detected PFO as reliably 
as more sensitive methods. Secondly, population-based 
studies may themselves been underpowered to detect the 
population-attributable fraction for stroke from PFO. 
Thirdly, the null hypothesis that PFO is not associated 
with stroke or migraine in unselected populations cannot 
Study Migraine
(PFO:no PFO)
Control
(PFO:no PFO)
Effect estimate
(95% CI)
CROSS-SECTIONAL DESIGN
Population-based sample
Migraine (OR)
Rundek, 2008 [45] 26:152 138:804 1.01 (0.63, 1.61)
Community-convenience sample
Migraine (OR)
Garg, 2010 [46] 38:106 37:107 1.04 (0.64, 1.74)
Hospital-convenience sample
Migraine (OR)
Tatlidede, 2007 [47] 28:25 6:21 3.92 (1.36, 11.30)
0.25 0.5 1 2 4 8 16
 Fig. 4. Meta-analysis of the reported associations between PFO and migraine (by study design and sampling 
frame). Forest plot showing results of meta-analysis. Studies are grouped by design and sampling frame. Black 
squares are proportional to the study size, lines represent 95% confidence intervals. 
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be rejected. Therefore, there are general implications for 
trials considering PFO closure in terms of how to assess 
PFO, which subpopulations to sample and the sample size 
required to demonstrate a modifiable effect.
 Relationship to Other Meta-Analyses 
 Previous meta-analyses have separately examined the 
relationships reviewed here. With regard to migraine and 
ischemic stroke, two recent systematic reviews have been 
conducted  [13, 54] . The eligibility criteria in these reviews 
did not specifically focus on cryptogenic stroke and in-
cluded a larger number of studies. One review pooled – 
with equal weighting – evidence across cohort (HR) and 
case-control studies (OR), finding an association mea-
sure of 2.2 (95% CI 1.5–3.0)  [13] . The other meta-analysis 
adopted similar methods but included a separate analysis 
restricted to studies at low risk of bias as determined by 
the authors (fewer than three ‘poor’ scores in different 
areas of the study design), in essence assigning an overall 
score for quality  [54] . However, even in the analysis re-
stricted to high-quality studies, the statistical heteroge-
neity was still sufficiently high to require a random-ef-
fects meta-analysis (I 2 = 68%). Because this in effect com-
bines studies across different populations, it is no longer 
clear to which population the pooled estimate then ap-
plies. Assigning an overall quality score does not in itself 
address the biases within individual studies. We avoided 
this by stratifying our analyses where risk of bias due to 
study design and population sampling is likely to be sim-
ilar across studies.
 Two systematic reviews on the relationship between 
PFO and cryptogenic ischemic stroke have been pub-
lished  [14, 55] . Both of these only examined case-control 
studies, thus do not account for evidence derived from 
prospective studies, and their results are consequently 
less conservative than ours, where the PFO-stroke asso-
ciation was estimated as OR of 3.0 (95% CI 2.0–4.3) for 
studies of PFO in cryptogenic stroke compared to non-
stroke controls  [55] . For the PFO-migraine association, 
another meta-analysis demonstrated an OR of 2.5 (95% 
CI 2.0–3.1; PFO in migraineurs) and an OR of 5.1 (95% 
CI 4.7–5.6; migraine in PFO patients)  [15] , though the 
systematic review predated the NOMAS report and also 
acknowledged that publication bias was likely. Two ab-
stracts await full publication but appear to report asso-
ciations in population-based samples. The Genetic Epi-
demiology of Migraine (GEM) study found migraine and 
PFO to be related only where PFO was also associated 
with an atrial septal aneurysm  [48] . CAMERA is a MRI 
substudy of GEM, reporting a significant association in 
migraine with aura and PFO (OR 2.1; 95% CI 1.1–3.9)  [49] . 
However, it is unlikely that pooling the preliminary result 
with the NOMAS data would substantially alter these 
conclusions given that NOMAS is a much larger study.
 Implications for Randomized Trials 
 The findings of this systematic review have implica-
tions for trials of PFO closure. If the underlying associa-
tion is weaker than previously recognized (or non-exis-
tent), detecting a treatment effect may require enormous 
sample sizes (or may be impossible). However, if random-
ized trials demonstrate a treatment effect, this would pro-
vide evidence not only for an association between PFO 
and ischemic stroke or migraine, but one that is causal. 
 Our findings may account for the results of the CLO-
SURE trial  [12] . The trial had an event rate (TIA and 
stroke) of 6% in the control arm and 2% in the closure 
arm. Also considering adverse effects of treatment, there 
were 7.7 and 5.9% events in the control and intervention 
groups, respectively (p = 0.30). Regardless of the concerns 
surrounding peri-procedural atrial fibrillation in this 
and other cohorts  [56] , one interpretation of the trial is 
that the underlying association is too small to be modi-
fied by an intervention with this efficacy. 
 The Migraine Intervention With STARFlex Technol-
ogy (MIST) trial is the only double-blinded sham-con-
trolled intervention trial in patients with refractory mi-
graine with aura  [11] . Though questions remain in re-
spect of the possibility that interatrial shunts were not 
completely closed  [57, 58] , the reported data suggest no 
benefit of PFO closure on migraine. It has been proposed 
that MIST participants were not representative of those 
in whom treatment benefit was observed in uncontrolled 
trials (i.e. those migraineurs spontaneously improving 
after PFO closure for cryptogenic stroke)  [59] . This ob-
servation is supported by the community-based studies 
finding no association between migraine and PFO in 
stroke-free populations identified in this review.  
 Conclusions 
 Our findings do not support an association between 
PFO in patients with cryptogenic ischemic stroke. Be-
cause the weak association between PFO and ischemic 
stroke in methodologically rigorous studies questions the 
causal role of PFO, randomized controlled trials of PFO 
closure constitute an essential test of the causal relation-
ship. However, the weakness of the association in obser-
vational epidemiological studies, as well as the effective-
 Patent Foramen Ovale, Stroke and 
Migraine 
Neuroepidemiology 2013;40:56–67 65
ness of antithrombotic drugs in the secondary prevention 
of ischemic stroke  [60] , means that ongoing and future 
trials of PFO closure will need to be very large. PFO clo-
sure may be more effective in subgroups with a stronger 
association with ischemic stroke (and therefore at highest 
risk of future cardioembolism), possibly in persons with 
very large PFO shunts  [32] or PFO associated with atrial 
septal aneurysm  [48] .
 Acknowledgement 
 D.D. is funded by a Wellcome research training fellowship. 
J.G. is sponsored by a joint MRC/GlaxoSmithKline industrial 
CASE studentship. P.W. is supported by a non-clinical PhD stu-
dentship from the British Heart Foundation. B.S. is funded by the 
Joint European Post-Doctoral Programme: The European Re-
search Area in Ageing (ERA-AGE) Network FLARE Programme. 
R.A.-S.S. was funded by a UK Medical Research Council clinician 
scientist fellowship.
 Supporting Information 
 Study characteristics of all included studies are given in full, 
along with referenced PRISMA flowchart detailing excluded 
studies. The MOOSE checklist is also submitted.
 Disclosure Statement 
 The authors have no conflict of interest to declare.
 
 References 
 1 Guercini F, Acciarresi M, Agnelli G, Paciaroni 
M: Cryptogenic stroke: time to determine ae-
tiology. J Thromb Haemost 2008; 6: 549–554. 
 2 Sacco RL, Adams R, Albers G, Alberts MJ, 
Benavente O, Furie K, Goldstein LB, Gore-
lick P, Halperin J, Harbaugh R, Johnston SC, 
Katzan I, Kelly-Hayes M, Kenton EJ, Marks 
M, Schwamm LH, Tomsick T: Guidelines for 
prevention of stroke in patients with isch-
emic stroke or transient ischemic attack: a 
statement for healthcare professionals from 
the American Heart Association/American 
Stroke Association Council on Stroke: co-
sponsored by the Council on Cardiovascular 
Radiology and Intervention: the American 
Academy of Neurology affirms the value of 
this guideline. Stroke 2006; 37: 577–617. 
 3 Goldstein LB, Adams R, Alberts MJ, Appel 
LJ, Brass LM, Bushnell CD, Culebras A, De-
graba TJ, Gorelick PB, Guyton JR, Hart RG, 
Howard G, Kelly-Hayes M, Nixon JV, Sacco 
RL: Primary prevention of ischemic stroke: a 
guideline from the American Heart Associa-
tion/American Stroke Association Stroke 
Council: cosponsored by the Atherosclerotic 
Peripheral Vascular Disease Interdisciplin-
ary Working Group; Cardiovascular Nurs-
ing Council; Clinical Cardiology Council; 
Nutrition, Physical Activity, and Metabo-
lism Council; and the Quality of Care and 
Outcomes Research Interdisciplinary Work-
ing Group: the American Academy of Neu-
rology affirms the value of this guideline. 
Stroke 2006; 37: 1583–1633. 
 4 Windecker S, Wahl A, Chatterjee T, Ga-
rachemani A, Eberli FR, Seiler C, Meier B: 
Percutaneous closure of patent foramen ova-
le in patients with paradoxical embolism: 
long-term risk of recurrent thromboembolic 
events. Circulation 2000; 101: 893–898. 
 5 Bridges ND, Hellenbrand W, Latson L, Filia-
no J, Newburger JW, Lock JE: Transcatheter 
closure of patent foramen ovale after pre-
sumed paradoxical embolism. Circulation 
1992; 86: 1902–1908. 
 6 Martin F, Sanchez PL, Doherty E, Colon-
Hernandez PJ, Delgado G, Inglessis I, Scott 
N, Hung J, King ME, Buonanno F, Demirjian 
Z, de Moor M, Palacios IF: Percutaneous 
transcatheter closure of patent foramen ova-
le in patients with paradoxical embolism. 
Circulation 2002; 106: 1121–1126. 
 7 Wilmshurst PT, Nightingale S, Walsh KP, 
Morrison WL: Effect on migraine of closure 
of cardiac right-to-left shunts to prevent re-
currence of decompression illness or stroke 
or for haemodynamic reasons. Lancet 2000; 
 356: 1648–1651. 
 8 Azarbal B, Tobis J, Suh W, Chan V, Dao C, 
Gaster R: Association of interatrial shunts 
and migraine headaches: impact of trans-
catheter closure. J Am Coll Cardiol 2005; 45: 
 489–492. 
 9 Reisman M, Christofferson RD, Jesurum J, 
Olsen JV, Spencer MP, Krabill KA, Diehl L, 
Aurora S, Gray WA: Migraine headache relief 
after transcatheter closure of patent foramen 
ovale. J Am Coll Cardiol 2005; 45: 493–495. 
 10 Schwerzmann M, Wiher S, Nedeltchev K, 
Mattle HP, Wahl A, Seiler C, Meier B, Win-
decker S: Percutaneous closure of patent fo-
ramen ovale reduces the frequency of mi-
graine attacks. Neurology 2004; 62: 1399–
1401. 
 11 Dowson A, Mullen MJ, Peatfield R, Muir K, 
Khan AA, Wells C, Lipscombe SL, Rees T, De 
Giovanni JV, Morrison WL, Hildick-Smith 
D, Elrington G, Hillis WS, Malik IS,
Rickards A: Migraine Intervention with 
STARFlex Technology (MIST) trial: a pro-
spective, multicenter, double-blind, sham-
controlled trial to evaluate the effectiveness 
of patent foramen ovale closure with 
STARFlex septal repair implant to resolve re-
fractory migraine headache. Circulation 
2008; 117: 1397–1404. 
 12 Furlan AJ, Reisman M, Massaro J, Mauri L, 
Adams H, Albers GW, Felberg R, Herrmann 
H, Kar S, Landzberg M, Raizner A, Wechsler 
L: Closure or medical therapy for cryptogen-
ic stroke with patent foramen ovale. N Engl J 
Med 2012; 366: 991–999. 
 13 Schurks M, Rist PM, Bigal ME, Buring JE, 
Lipton RB, Kurth T: Migraine and cardio-
vascular disease: systematic review and me-
ta-analysis. BMJ 2009; 339:b3914. 
 14 Alsheikh-Ali AA, Thaler DE, Kent DM: Pat-
ent foramen ovale in cryptogenic stroke: in-
cidental or pathogenic? Stroke 2009;  40: 
 2349–2355. 
 15 Schwedt TJ, Demaerschalk BM, Dodick DW: 
Patent foramen ovale and migraine: a quan-
titative systematic review. Cephalalgia 2008; 
 28: 531–540. 
 16 Egger M, Schneider M, Davey Smith G: Spu-
rious precision? Meta-analysis of observa-
tional studies. BMJ 1998; 316: 140–144. 
 17 Stroup DF, Berlin JA, Morton SC, Olkin I, 
Williamson GD, Rennie D, Moher D, Becker 
BJ, Sipe TA, Thacker SB: Meta-analysis of ob-
servational studies in epidemiology: a pro-
posal for reporting. Meta-analysis Of Obser-
vational Studies in Epidemiology (MOOSE) 
group. JAMA 2000; 283: 2008–2012. 
 Davis  /Gregson  /Willeit  /Stephan  /
Al-Shahi Salman  /Brayne  
 
Neuroepidemiology 2013;40:56–6766
 18 Headache Classification Subcommittee of 
the International Headache Society: The In-
ternational Classification of Headache Dis-
orders: 2nd edition. Cephalalgia 2004; 
 24(suppl 1):9–160. 
 19 Classification and diagnostic criteria for 
headache disorders, cranial neuralgias and 
facial pain. Headache Classification Com-
mittee of the International Headache Soci-
ety. Cephalalgia 1988; 8(suppl 7):1–96. 
 20 Wells GA, Shea B, O’Connell D, Peterson J, 
Welch V, Losos M, Tugwell P: The Newcas-
tle-Ottawa Scale (NOS) for assessing the 
quality of nonrandomised studies in meta-
analyses. http://www.Ohri.Ca/programs/
clinical_epidemiology/oxford.Asp (accessed 
September 9, 2012). 
 21 Kurth T, Gaziano JM, Cook NR, Logroscino 
G, Diener HC, Buring JE: Migraine and risk 
of cardiovascular disease in women. JAMA 
2006; 296: 283–291. 
 22 MacClellan LR, Giles W, Cole J, Wozniak M, 
Stern B, Mitchell BD, Kittner SJ: Probable 
migraine with visual aura and risk of isch-
emic stroke: The stroke prevention in young 
women study. Stroke 2007; 38: 2438–2445. 
 23 Schwaag S, Nabavi DG, Frese A, Husstedt 
IW, Evers S: The association between mi-
graine and juvenile stroke: a case-control 
study. Headache 2003; 43: 90–95. 
 24 Carolei A, Marini C, De Matteis G: History 
of migraine and risk of cerebral ischaemia in 
young adults. The Italian National Research 
Council Study Group on Stroke in the Young. 
Lancet 1996; 347: 1503–1506. 
 25 Tzourio C, Tehindrazanarivelo A, Iglesias S, 
Alperovitch A, Chedru F, d’Anglejan-Cha-
tillon J, Bousser MG: Case-control study of 
migraine and risk of ischaemic stroke in 
young women. BMJ 1995; 310: 830–833. 
 26 Tzourio C, Iglesias S, Hubert JB, Visy JM, 
Alperovitch A, Tehindrazanarivelo A, Bi-
ousse V, Woimant F, Bousser MG: Migraine 
and risk of ischaemic stroke: a case-control 
study. BMJ 1993; 307: 289–292. 
 27 Chang CL, Donaghy M, Poulter N: Migraine 
and stroke in young women: Case-control 
study. The World Health Organisation Col-
laborative Study of Cardiovascular Disease 
and Steroid Hormone Contraception. BMJ 
1999; 318: 13–18. 
 28 Barinagarrementeria F, Gonzalez-Duarte A, 
Miranda L, Cantu C: Cerebral infarction in 
young women: analysis of 130 cases. Eur 
Neurol 1998; 40: 228–233. 
 29 Henrich JB, Horwitz RI: A controlled study 
of ischemic stroke risk in migraine patients. 
J Clin Epidemiol 1989; 42: 773–780. 
 30 Meissner I, Khandheria BK, Heit JA, Petty 
GW, Sheps SG, Schwartz GL, Whisnant JP, 
Wiebers DO, Covalt JL, Petterson TM, 
Christianson TJ, Agmon Y: Patent foramen 
ovale: innocent or guilty? Evidence from a 
prospective population-based study. J Am 
Coll Cardiol 2006; 47: 440–445. 
 31 Di Tullio MR, Sacco RL, Sciacca RR, Jin Z, 
Homma S: Patent foramen ovale and the risk 
of ischemic stroke in a multiethnic popula-
tion. J Am Coll Cardiol 2007; 49: 797–802. 
 32 Sastry S, Riding G, Morris J, Taberner D, 
Cherry N, Heagerty A, McCollum C: Young 
Adult Myocardial Infarction and Ischemic 
Stroke: the role of paradoxical embolism and 
thrombophilia (The YAMIS Study). J Am 
Coll Cardiol 2006; 48: 686–691. 
 33 Petty GW, Khandheria BK, Meissner I, 
Whisnant JP, Rocca WA, Christianson TJ, 
Sicks JD, O’Fallon WM, McClelland RL, 
Wiebers DO: Population-based study of the 
relationship between patent foramen ovale 
and cerebrovascular ischemic events. Mayo 
Clin Proc 2006; 81: 602–608. 
 34 Roijer A, Lindgren A, Algotsson L, Norrving 
B, Olsson B, Eskilsson J: Cardiac changes in 
stroke patients and controls evaluated with 
transoesophageal echocardiography. Scand 
Cardiovasc J 1997; 31: 329–337. 
 35 Serena J, Segura T, Perez-Ayuso MJ, Bassag-
anyas J, Molins A, Davalos A: The need to 
quantify right-to-left shunt in acute ischemic 
stroke: a case-control study. Stroke 1998; 29: 
 1322–1328. 
 36 Jones EF, Calafiore P, Donnan GA, Tonkin 
AM: Evidence that patent foramen ovale is 
not a risk factor for cerebral ischemia in the 
elderly. Am J Cardiol 1994; 74: 596–599. 
 37 Mattioli AV, Bonetti L, Aquilina M, Oldani 
A, Longhini C, Mattioli G: Association be-
tween atrial septal aneurysm and patent fo-
ramen ovale in young patients with recent 
stroke and normal carotid arteries. Cerebro-
vasc Dis 2003; 15: 4–10. 
 38 Cabanes L, Mas JL, Cohen A, Amarenco P, 
Cabanes PA, Oubary P, Chedru F, Guerin F, 
Bousser MG, de Recondo J: Atrial septal an-
eurysm and patent foramen ovale as risk fac-
tors for cryptogenic stroke in patients less 
than 55 years of age. A study using trans-
esophageal echocardiography. Stroke 1993; 
 24: 1865–1873. 
 39 Schuchlenz HW, Weihs W, Horner S, Que-
henberger F: The association between the di-
ameter of a patent foramen ovale and the risk 
of embolic cerebrovascular events. Am J Med 
2000; 109: 456–462. 
 40 Cerrato P, Imperiale D, Priano L, Mangiardi 
L, Morello M, Marson AM, Carra F, Barber-
is G, Bergamasco B: Transoesophageal echo-
cardiography in patients without arterial 
and major cardiac sources of embolism: dif-
ference between stroke subtypes. Cerebro-
vasc Dis 2002; 13: 174–183. 
 41 Di Tullio M, Sacco RL, Gopal A, Mohr JP, 
Homma S: Patent foramen ovale as a risk fac-
tor for cryptogenic stroke. Ann Intern Med 
1992; 117: 461–465. 
 42 Force M, Massabuau P, Larrue V: Prevalence 
of atrial septal abnormalities in older pa-
tients with cryptogenic ischemic stroke or 
transient ischemic attack. Clin Neurol Neu-
rosurg 2008; 110: 779–783. 
 43 Handke M, Harloff A, Olschewski M, Hetzel 
A, Geibel A: Patent foramen ovale and cryp-
togenic stroke in older patients. N Engl J Med 
2007; 357: 2262–2268. 
 44 Negrao EM, Brandi IV, Nunes SV, Tavora 
DG, Nakayama M, Beraldo PS: Patent fora-
men ovale and ischemic stroke in young peo-
ple: statistical association or causal relation? 
Arq Bras Cardiol 2007; 88: 514–520. 
 45 Rundek T, Elkind MS, Di Tullio MR, Carrera 
E, Jin Z, Sacco RL, Homma S: Patent foramen 
ovale and migraine: a cross-sectional study 
from the Northern Manhattan Study (NO-
MAS). Circulation 2008; 118: 1419–1424. 
 46 Garg P, Servoss SJ, Wu JC, Bajwa ZH, Selim 
MH, Dineen A, Kuntz RE, Cook EF, Mauri 
L: Lack of association between migraine 
headache and patent foramen ovale: results 
of a case-control study. Circulation 2010; 121: 
 1406–1412. 
 47 Tatlidede AD, Oflazoglu B, Celik SE, Anadol 
U, Forta H: Prevalence of patent foramen 
ovale in patients with migraine. Agri 2007; 
 19: 39–42. 
 48 De Heij AH, Luermans JGLM, Thijs V, 
Schonewille W, Plokker HWM, Budts W, 
Post MC: Patent foramen ovale with atrial 
septal aneurysm is a strong independent pre-
dictor for migraine with aura: a large pro-
spective observational study. Eur Heart J 
2010; 31: 865. 
 49 Koppen H, Palm-Meinders IH, Mess WH, 
Keunen RW, Terwindt GM, Launer LJ, Van 
Buchem MA, Ferrari MD, Kruit MC: Popu-
lation-based evidence for an association be-
tween migraine and right-to-left shunt 
(PFO). Cephalalgia 2009; 29: 1352. 
 50 Conen D, Chae CU, Glynn RJ, Tedrow UB, 
Everett BM, Buring JE, Albert CM: Risk of 
death and cardiovascular events in initially 
healthy women with new-onset atrial fibril-
lation. JAMA 2011; 305: 2080–2087. 
 51 Mas JL, Arquizan C, Lamy C, Zuber M, Ca-
banes L, Derumeaux G, Coste J: Recurrent 
cerebrovascular events associated with pat-
ent foramen ovale, atrial septal aneurysm, or 
both. N Engl J Med 2001; 345: 1740–1746. 
 52 Feurer R, Sadikovic S, Sepp D, Esposito L, 
Schleef M, Bockelbrink A, Schwarze J, Hem-
mer B, Sander D, Poppert H: Patent foramen 
ovale is not associated with an increased risk 
of stroke recurrence. Eur J Neurol 2010; 17: 
 1339–1345. 
 53 Ioannidis JP, Patsopoulos NA, Rothstein 
HR: Reasons or excuses for avoiding meta-
analysis in forest plots. BMJ 2008; 336: 1413–
1415. 
 54 Spector JT, Kahn SR, Jones MR, Jayakumar 
M, Dalal D, Nazarian S: Migraine headache 
and ischemic stroke risk: an updated meta-
analysis. Am J Med 2010; 123: 612–624. 
 55 Overell JR, Bone I, Lees KR: Interatrial septal 
abnormalities and stroke: a meta-analysis of 
case-control studies. Neurology 2000;  55: 
 1172–1179. 
 Patent Foramen Ovale, Stroke and 
Migraine 
Neuroepidemiology 2013;40:56–67 67
 56 Wahl A, Meier B, Haxel B, Nedeltchev K, Ar-
nold M, Eicher E, Sturzenegger M, Seiler C, 
Mattle HP, Windecker S: Prognosis after per-
cutaneous closure of patent foramen ovale 
for paradoxical embolism. Neurology 2001; 
 57: 1330–1332. 
 57 Carroll JD: Migraine Intervention with 
STARFlex Technology trial: a controversial 
trial of migraine and patent foramen ovale 
closure. Circulation 2008; 117: 1358–1360. 
 58 Gornall J: A very public break-up. BMJ 2010; 
 340:c110. 
 59 Gersony WM, Gersony DR: Migraine head-
ache and the patent foramen ovale. Circula-
tion 2010; 121: 1377–1378. 
 60 Rothwell PM, Algra A, Amarenco P: Medical 
treatment in acute and long-term secondary 
prevention after transient ischaemic attack 
and ischaemic stroke. Lancet 2011; 377: 1681–
1692. 
 61 De Castro S, Cartoni D, Fiorelli M, Rasura M, 
Anzini A, Zanette EM, Beccia M, Colonnese 
C, Fedele F, Fieschi C, Pandian NG: Morpho-
logical and functional characteristics of pat-
ent foramen ovale and their embolic implica-
tions. Stroke 2000; 31: 2407–2413. 
 62 Serena J, Marti-Fabregas J, Santamarina E, 
Rodriguez JJ, Perez-Ayuso MJ, Masjuan J, 
Segura T, Gallego J, Davalos A: Recurrent 
stroke and massive right-to-left shunt: Re-
sults from the prospective Spanish multi-
center (CODICIA) study. Stroke 2008; 39: 
 3131–3136. 
 63 Comess KA, DeRook FA, Beach KW, Lytle 
NJ, Golby AJ, Albers GW: Transesophageal 
echocardiography and carotid ultrasound in 
patients with cerebral ischemia: prevalence 
of findings and recurrent stroke risk. J Am 
Coll Cardiol 1994; 23: 1598–1603. 
 64 Cujec B, Mainra R, Jonhson DH: Prevention 
of recurrent cerebral ischemic events in pa-
tients with patent foramen ovale and crypto-
genic strokes or transient ischemic attacks. 
Can J Cardiol 1999;15:57–64. 
 65 Chen WJ, Lin SL, Chen JJ, Lien WP: The fre-
quency of patent foramen ovale in patients 
with ischemic stroke: a transesophageal 
echocardiographic study. J Formos Med As-
soc 1991;90:744–748. 
